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Abstract 
Introduction: A significant proportion of patients undergoing radical nephrectomy 
(RN) for clear-cell renal cell carcinoma (RCC) develop chronic kidney disease (CKD) 
within a few years following surgery.  CKD has important health, social and economic 
impact and no predictive biomarkers are currently available.  MicroRNAs (miRs) are 
small non-coding RNAs implicated in several pathological processes.  
Methods: Primary objective of our study was to define miRs whose deregulation is 
predictive of CKD in patients treated with RN. RNA from formalin fixed paraffin 
embedded renal parenchyma (cortex and medulla isolated separately) situated >3cm 
from the matching RCC was tested for miR expression using nCounter NanoString 
technology in 71 consecutive patients treated with RN for RCC.  Validation was 
performed by Real-Time PCR and In-Situ Hybridization (ISH). Endpoint was post-RN 
CKD measured 12 months post-operatively.  Multivariable logistic regression and 
Decision Curve Analysis were used to test the statistical and clinical impact of 
predictors of CKD.   
Results: miR-193b-3p over-expression was associated with high risk of developing 
CKD in patients undergoing RN for RCC and emerged as an independent predictor 
of CKD.  The addition of miR-193b-3p to a predictive model based on clinical 
variables (including sex and estimated Glomerular Filtration Rate) increased the 
sensitivity of the predictive model from 81% to 88%. ISH showed that miR-193b-3p 
over-expression was associated with tubule-interstitial inflammation and fibrosis in 
patients with no clinical or biochemical evidence of pre-RN nephropathy.     
Conclusions: miR-193b-3p might represent a useful biomarker to tailor and 
implement surveillance strategies for patients at high risk of developing CKD 
following RN. 
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Introduction 
Renal clear-cell carcinoma (RCC) is the most common type of kidney tumor in 
adults (85%) and accounts for 3% of all malignancies (Ferlay et al, 2013; Siegel et al, 
2016).  Surgery represents the gold standard for the treatment of clinically localized 
RCC (Ljungberg et al, 2015).  While oncological outcomes (in tumors measuring less 
than 4 cm) are similar in radical nephrectomy (RN) and in nephron sparing surgery 
(NSS), the incidence of long term morbidity due to the development of chronic kidney 
disease (CKD) is higher in the case of RN due to the loss of nephron mass 
(Capitanio et al, 2016).  CKD affects quality of life and life expectancy and has 
important health-economic implications being associated with increased 
cardiovascular risk, metabolic syndromes and end-stage kidney disease (Nashar & 
Egan, 2014).  
Even though several mechanisms for the decay in renal function following RN 
have been hypothesized, no predictive markers are currently available to inform 
clinicians of the risk of developing CKD and to tailor surveillance and secondary 
prevention programs (Capitanio et al, 2016).  
MicroRNAs (miRs) are short (19-24 nucleotides) non-protein coding RNAs fine 
tuning cell homeostasis by controlling gene expression at post-transcriptional level 
(Fabbri et al, 2009; Winter et al, 2009).  MiRs are implicated in renal physiology 
regulating ion transport, electrolytes and acid-base equilibrium as well as blood 
pressure (Elvira-Matelot et al, 2010; Mladinov et al, 2013; Trionfini et al, 2015).  MiRs 
deregulation is common to many cancers as well as infectious, cardiovascular, 
metabolic and kidney diseases and it can be exploited for screening, diagnosis and 
treatment (Catto et al, 2011; Fasanaro et al, 2015; Mendell & Olson, 2012; Trionfini 
et al, 2015). 
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In the current study, we aimed to test miR deregulation in “normal” kidney 
tissue in patients with and without deterioration in renal function after RN for RCC, in 
order to define predictive biomarkers of CKD.   
 
Methods 
Study population 
One-hundred and five patients treated with RN for RCC at San Raffaele 
Hospital (Milan, Italy) between 2008 and 2013 were eligible for the study.  The 
project has been approved by the relevant Ethic Committee (approval 
2007/29082007/V3) and informed consent is available for each patient.  The 
inclusion criteria of the study were: (a) age >18 and < 80 years ; (b) clear-cell 
carcinoma histology; (c) resectable RCC and absence of metastatic within the initial 
12 months from diagnosis; (d) no history of other malignancies; (e) normal renal 
function prior to RN, estimated Glomerular Fraction Rate (eGFR) > 60 ml/min (CKD-
EPI formula 2009 (Eknoyan et al, 2013)), serum creatinine less than 1.1 mg/dl and 
no urinary abnormalities (i.e. proteinuria); (f) absence of primitive, secondary, 
hereditary or acquired glomerulopathies; (g) absence of kidney stone disease, 
myeloproliferative disorders, autoimmune diseases (i.e. vasculitis and systemic 
infections); (h) absence of chronic nephrotoxic drug therapy (eg. lithium, NSAID).  All 
patients underwent post-operative review one month after RN and 6-montly follow-up 
with physical examination, lab test and CT scan thereafter. 
Twelve renal biopsies (cortex only) from kidney donors [Remuzzi score ≤4 
(Remuzzi et al, 1999)] were collected from the archives of the Surgical Pathology 
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Unit at Padua University (Padua, Italy) and used as controls (Ethic Committee 
approval #: 0011418 - 02/03/2015).   
 
Pathology Review 
Hematoxylin and eosin stained slides from 100 formalin-fixed paraffin-
embedded (FFPE) tissues were reviewed by a pathologist. Only samples > 3 cm 
distance from RCC were considered. Renal cortex and medulla were manually micro-
dissected in order to separate the glomerular region from the loop of Henle and 
collecting ducts. Twenty cases were excluded due to inadequate representation of 
the cortex region (less than 10 glomeruli on 10x field of view), because this might 
have impaired the yield of RNA from the glomeruli. 
Total RNA extraction was performed using Ambion Recover All Isolation Kit 
(LifeTechnologies, Carlsbad, USA), according to the manufacturer’s instructions. The 
purity and quality of extracted RNA was determined by Bio-Analyser (Agilent 
Technologies, Santa Clara, USA). 9 samples were discarded due to poor RNA 
quality/quality.  
 
NanoString nCounter and Bioinformatics analysis 
MiR expression was analyzed using the nCounter Human v2 miR Expression 
Assay kit (NanoString, Seattle, Washington, USA) as we previously described (Valeri 
et al, 2014).  This assay detects 800 endogenous miRNAs, five housekeeping 
transcripts plus six positive and six negative controls. 150ng of each total RNA 
sample was used as input into the nCounter Human miR sample preparation. 
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Hybridization was conducted for 16h at 65°C. Subsequently, the strip tubes were 
placed into the nCounter Prep Station for automated sample purification and 
subsequent reporter capture. Each sample was scanned for 555 fields of view on the 
nCounter Digital Analyzer.  Data were extracted using the nCounter RCC Collector 
(NanoString, Seattle, Washington, USA).  Two samples, one medulla from a patient 
with normal kidney function and one cortex from a healthy kidney donor, failed quality 
control and were excluded from further analysis. 
Raw data, which are proportional to copy number, were log-transformed and 
normalized by the quantile method after application of a manufacturer-supplied 
correction factor for several miR (Cascione et al, 2013).  Data were filtered to exclude 
relatively invariant features (IQR = 0.5) and features below the detection threshold 
(defined for each sample by a cut-off corresponding to approximately 2 x standard 
deviation of negative control probes plus the mean of them) in at least half of the 
samples. After the pre-processing steps described above, we plotted the relative 
differences in transcriptional profile between the samples using multi-dimensional 
scaling (MDS) plot.  Using R/Bioconductor and the filtered dataset, Significance 
Analysis of Microarrays was employed with a contrast matrix for the comparisons 
(Cascione et al, 2013).  P-values were used to rank miRs of interest, and correction 
for multiple comparisons was performed using the Benjamini-Hocheberg method 
(Benjamini & Hochberg, 1995).  Raw data that were above background, as well as 
the corresponding quantile-normalized data, were imported into MultiExperiment 
Viewer (http://mev.tm4.org/) for visual inspection. 
Heatmaps were generated using the Euclidean Distance as metric distance 
and a Single Clustering as linkage criterion.  Only miRs with a t-test p-value less than 
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0.1 were included in the heatmaps.  The colour red indicates strong expression of a 
miR while a blue point mirrors a reduced level of a determined miR.  
MiR expression data have been submitted to GEO under accession number 
GSE80247.    
 
RT- PCR analysis 
Expression of four of the most importantly dysregulated miRs detected using 
NanoString nCounter Analysis (hsa-miR-193b-3p, hsa-miR-365a-3p, hsa-miR-363b-
3p, hsa-miR-139b-5p) was investigated by Real-Time PCR (RT-PCR) using 
Taqman™ assays (Life Technologies, Carlsbad, California, USA).  Comparative RT-
PCR was run in triplicate, including no-template controls and endogenous control 
gene RNU48. The fold difference for each sample was obtained using the ΔCT 
method.  
 
miR-193b In-situ hybridization (ISH) analysis 
Locked nucleic acid (LNA) probes with complementarity to miR-193b-3p were 
labelled with 5′-biotin and synthesized using Exiqon (Vedbaek, Denmark).  Tissue 
sections were digested with ISH protease 1 (Ventana Medical Systems, Milan, Italy) 
and ISH was performed as we previously described (Nuovo et al, 2012). Positive 
(U6; Exiqon, Vedbaek, Denmark) and negative scrambled LNA probes (Exiqon, 
Vedbaek, Denmark) were used as controls.  Only cytoplasmic miR staining was 
retained for scoring purposes. 
 
Statistical analyses 
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The endpoint of the study was the rate of de novo post-RN CKD defined as 
stage 3a-3b- 4 calculated 12 months after surgery (Eknoyan et al, 2013).  
First, the Mann-Whitney test was used to compare the statistical significance 
of differences in the distribution of each miR of interest according to CKD.  Second, 
multivariable logistic regression analysis (MVA) was used to construct a baseline 
model predicting the CKD relying on clinical predictors only. Such predictors were 
factors suggestive for increased risk of post-surgical CKD, and consisted of age, 
gender, baseline eGFR, clinical tumour size (defined as the largest tumour dimension 
at preoperative imaging), and presence of diabetes.  Third, each miR of interest was 
independently added to the baseline model, and the concordance index (CI) of each 
miR-inclusive model was compared to that of the baseline model.  Fourth, the net-
benefit of the baseline model and of each miR-inclusive model was assessed using 
decision curve analysis (Vickers & Elkin, 2006). 
 
Results 
Baseline Clinical Characteristics and Measure of Clinical Outcome 
Of the originally collected one-hundred and five patients with histologically 
proven, RCC treated with curative RN, 71 patients were included in our study for 
clinical and molecular predictors of CKD (34 patients were excluded from the 
analysis and details are shown in Figure 1). Patient characteristics are summarized 
in Table 1.  
Fourteen (20%) patients suffered from type II diabetes control by oral 
hypoglycaemic agents at time diagnosis; no patients had type I diabetes (Table 1). 
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Histological review of resection specimen ruled out signs of pre-existing nephropathy 
in all these patients. Similarly, none of the patients showed biochemical signs of CKD 
with normal renal function in absence of proteinuria.  
Physiological fluctuations in the eGFR are common in the post-RN setting, 
relate to compensatory nephron hyper-filtration in the contralateral kidney and, 
usually, occur within the initial 6 months from the operation.  Given that several lines 
of evidence suggest that a reduction in eGFR at 12 months from RN is associated 
with increased risk of CKD (Westland et al, 2014), our endpoint measurement was 
performed 12 months post-RN.  
Thirty-eight (54%) patients experienced a reduction in eGFR, developing a 
mild to severe chronic kidney disease 12 months post-RN. (Supplementary Figure 1A 
and 1B).   
 
Identification of microRNAs associated with CKD in the training cohort. 
In order to define miRs discriminating patients who developed CKD at 12 
months post-RN and patients with normal kidney function (NKF), we performed miR 
expression analysis in a randomly selected training cohort of 12 CKD and 12 NKF 
patients. Since CKD can be related to different abnormalities affecting the nephron, 
the cortex and medulla were dissected and tested for miR expression separately.  
Nine miRs were up-regulated and one was down-regulated greater than 1.5 fold (p-
value ≤0.05) in the comparison between CKD and NKF patients (irrespective of 
anatomic location) (Supplementary  Table S1).  
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When the analysis compared the medulla of CKD and NKF patients, ten miRs 
were found to be over-expressed more than 1.5 fold in CKD patients. No miR 
showed statistically significant down-regulation greater than 1.5 fold (Figure 2 and 
Supplementary Table S2).  Conversely, when the analysis focused on the cortex, two 
miRs were found to be up-regulated and one miR was down-regulated greater than 
1.5 fold in CKD patients (Supplementary Figure S2 and Table S3).   
 
Shortlisting and validation of miRs found to be de-regulated in CKD versus 
NKF patients. 
For the validation of miRs associated with the development of CKD we 
focused on miRs up-regulated in the comparison between medulla of CKD versus 
NKF patients based on the following observations: 1) CKD is largely due to early 
tubular dysfunction which promotes increased sodium reabsorption and glomerular 
hyper-filtration (Capitanio et al, 2016); 2) the comparison between medulla of CKD 
versus NKF provided more significantly deregulated miRs than the comparison 
between cortex of the same patients; 3) over-expressed rather than silenced miRs  
might be easier to detect in tissues and biological fluids.  
Expression of the four miRs (miR-193b-3p, miR-365a-3p, miR-363b-3p, miR-
139b-5p) deregulated in the medulla of CKD versus NKF patients detected in the 
training cohort by nCounter was confirmed in the same cohort (n=23) and validated in 
the remaining patients (n=47) by RT-PCR.  All four miRs were confirmed as 
significantly up-regulated in the cortex of CKD patients (Supplementary Table S4). 
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Clinical and Molecular Predictors of CKD  
In order to define clinical markers of CKD we performed a multivariable logistic 
regression analysis (MVA) which showed that gender [Odds Ratio (OR) 6.07; p=0.02] 
and pre-operative eGFR (OR 0.93; p=0.02) are independent predictors of CKD [base 
model (Table 2)].  The area under the curve (AUC) of the base model was 81%.  
When each miR was included in the base model, each miR emerged as an 
independent predictor of CKD after adjustment for clinical variables.  Specifically, 
miR-193b-3p (OR 2.28; p=0.002), miR-363b-3p, (OR 6.28; p=0.04), miR-139b-5p 
(OR 5.86; p=0.01) and miR-365a-3p (OR 2.18; p=0.01) were all associated with an 
increased risk of CKD.  Moreover, after the inclusion of miR193b-3p, miR363b-3p, 
miR139b-5p and miR365a-3p, the AUC of the base model increased to 88, 83, 86 
amd 86% respectively (Table 2).  At decision curve analyses (DCA), the inclusion of 
each miR into a baseline model predicting CKD using only clinical variables yielded a 
higher net-benefit (Figure 3).  In order to test whether the inclusion of multiple miRs 
to the basic model would yield higher predictive value we selected Model-1 (Table 2) 
as our base model (clinical-pathological variables + miR-193b-3p) and we added 
miR-363b-3p, miR-139b-5p and miR-365a-3p expression individually. None of these 
miRs increased the clinical and/or statistical power of the predictive model including 
miR-193b-3p alone (all p>0.05). Moreover, the inclusion of miR-363b, miR-139b and 
miR-365a in such model was associated with an AUC of 0.88, 0.89 and 0.89 
respectively, which do not differ from the AUC of our original model 1 including 
clinical pathological parameters + miR-193b expression (0.88). Based on these 
observations, we focused our attention on miR-193b-3p alone for further analysis.   
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MiR-193b-3p tissue of origin 
MiR expression is organ and tissue dependent (Lim et al, 2005). In order to 
validate the observations gathered from nCounter and RT-PCR data and provide 
insights in the role of these miRs in CKD pathogenesis, we performed miR-193b-3p 
ISH analysis in medulla and cortex tissues in samples characterized by high and low 
miR-193b-3p expression at nCounter and RT-PCR analysis in patients with high pre-
operative eGFR.   
In cases with low miR-193b-3p expression, faint miR-193b-3p staining was 
observed in the collector ducts (medulla), in distal convoluted tubule and in 
glomerular endothelial cells (cortex). High-miR-193b-3p cases were characterized by 
strong miR expression in the inflammatory infiltrate and in fibroblasts present in both 
renal regions.  Moreover, in keeping with the nCounter expression data, significant 
miR-193b-3p overexpression was observed in atrophic and swollen tubules and in 
ducts within the medulla (Figure 4). 
Cancer can cause re-wiring of miR and gene expression in adjacent 
surrounding tissues (Volinia et al, 2010). In order to test whether miR-193b-3p 
expression changes in renal parenchyma were caused by the cancer we compared 
global miR expression in patients who underwent RN for RCC with healthy kidney 
donors. Even though a global miR deregulation was observed in “normal” tissues 
surrounding cancer compared to healthy donors, miR-193b-3p was not among the 
deregulated miRs (Supplementary Figure S3 and S4 and Table S5). To support this 
observation, we also analysed miR-193b-3p expression in RCC patients in The 
Cancer Genome Atlas (TCGA (Cancer Genome Atlas Research, 2013)) dataset for 
whom cancer and matching normal miR-Seq data were available. Comparison of 
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cancer and adjacent tissues confirmed that miR-193b-3p is over-expressed by 40% 
(p<0.0001) in normal tissues adjacent to the cancer (Supplementary Figure S5). 
 
Discussion 
Three quarters of patients affected by Stage I-II RCC will survive more than 5 
years from the initial diagnosis (Karakiewicz et al, 2007). While several efforts to 
improve oncological outcome in early and metastatic RCC patients are ongoing, little 
has been done to reduce comorbidities and improve quality of life and outcome in 
cancer survivors.  
The incidence of CKD is increasing worldwide and the association between 
RN and increased risk of CKD is well documented (Mariusdottir et al, 2013), 
highlighting the unmet need for predictive bio-markers that might enable us to tailor 
patients’ surveillance and treatment.  
MiR deregulation has been studied in RCC and diabetes-related kidney 
disorders (Catto et al, 2011; Trionfini et al, 2015) but no study has linked miR 
deregulation with the risk of developing CKD in RN patients. 
Our study led to two main conclusions: 1) the use of miR-193b-3p improves 
the predictive value of clinical nomograms in estimating the risk of CKD; 2) miR-
193b-3p up-regulation is associated with morphological features of inflammation, 
fibrosis and atrophy in patients with no pre-operative clinical or bio-chemical 
evidence of kidney disease.   
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Our data rely on the retrospective analysis of a limited cohort of patients thus 
are not intended to change clinical practice. However, while prospective validation 
studies are ongoing, questions and avenues of future research have arisen.  
MiR-193b-3p has been previously characterized as a regulator of transcription 
factors such as MYB (Mets et al, 2015), down-stream effector of MAPK (Ikeda et al, 
2012) pathway and regulator of cell steaminess (Haetscher et al, 2015) in different 
tumour types including pancreatic cancers and leukaemia. Similarly, miR-193b-3p 
dysregulation has been detected in rheumatic disorders (Iwamoto et al, 2016), pre-
eclampsia (Xu et al, 2014) as well as inflammation in white adipose tissues (Arner et 
al, 2012) through the regulation of inflammatory chemokines. 
 In our cohort, miR-193b-3p over-expression is associated with inflammation 
and atrophy and can be detected in tubular, ductal and inflammatory cells suggesting 
cross-talk between different compartments in promoting inflammation and fibrosis.  
A reasonable question is whether the cancer is promoting inflammatory 
changes and miR-193b-3p over-expression. It is worth noticing that miR-193b-3p up-
regulation was independent of tumour and/or kidney size and no evidence of 
compression from the cancer was observed on histological review, excluding an 
indirect effect of malignancy in promoting an inflammatory/hypoxic reaction in the 
normal counterpart.  Exosome transfer of miR has been widely studied in the 
interaction between tumour and its surrounding tissues (Neviani & Fabbri, 2015) thus 
it is legitimate to speculate that over-expression of miR-193b-3p in cancer could have 
driven the phenotype we observed. Some observations however argue against this 
theory, as the analysis of an independent cohort of RCC cases and matching 
controls included in the TCGA dataset revealed a down-regulation of miR-193b-3p in 
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cancer compared to normal tissues; an observation that fits with several reports 
suggesting a tumour suppressor role for miR-193b-3p (Gastaldi et al, 2014; Mets et 
al, 2015). Further evidence supporting this hypothesis is represented by the 
comparison of RCC matched normal tissues versus healthy kidney donors. Even 
though a general re-wiring of miR expression, possibly due to the cancer 
microenvironment, was observed, miR-193b-3p was not found to be de-regulated in 
this comparison, suggesting that its up-regulation might be independent from cancer.   
MVA for CKD suggested that basal eGFR was an independent predictor of 
CKD; however, even patients with high basal eGFR experienced a pathological 
reduction in glomerular filtration. As suggested by ISH analysis these patients 
showed early morphological signs of tubular-glomerular sclerosis associated with 
miR-193b-3p up-regulation providing an explanation for the improved predictive value 
of the decision curve analyses when both parameters were included.   
Similar to our observations, miR-193b-3p has been found to be up-regulated in 
tissues and urine in patients with kidney interstitial fibrosis, tubular atrophy and acute 
kidney rejection, suggesting that this miR might be involved in pro-inflammatory 
feedback involving the interstitial compartment (Maluf et al, 2014; Wilflingseder et al, 
2013).   
The observation that miR-193b-3p up-regulation appears independent from 
the cancer microenvironment and common to other inflammatory tubular-interstitial 
nephropathies led us to speculate that it might be indicative of a pre-existing, 
clinically and biochemically undetectable, disease potentially also affecting the 
contralateral kidney. In this scenario, the acute loss of nephron mass caused by 
nephrectomy could trigger hyper-filtration mechanisms which in the presence of 
18 
 
tubular atrophy and fibrosis in the remaining kidney could irreversibly compromise 
the tubular-glomerular feedback. Under these circumstances, afferent arteriolar 
vasodilatation, increased renal perfusion and stress for the glomeruli might translate 
into CKD within 12 months from the operation. 
An interesting consideration is whether miR-193b-3p might be combined with 
other miRs to form a signature and whether this would be more accurate in defining 
the prognosis of RN patients than miR-193b-3p alone. We tested this hypothesis and 
we showed that including multiple miRs in the predictive model does not increase the 
performance of the model. Two potential explanations might justify this observation: 
a) there is collinearity in miR193b-3p and miR-363b-3p, miR-139b-5p and miR-365a-
3p expression and as such there is no added predictive value in incorporating them 
together; b) the number of events (patients with eGFR derangement at 12 months 
post-RN) in our study is too limited to pick up a difference in predictive value.   
While the identification of miR-193b-3p targets is beyond the scope of our 
work, it is worth mentioning that several key features of CKD such as inflammatory 
cell infiltration, tubular cell atrophy, mesangial cell hypertrophy and podocyte 
apoptosis are linked to transforming growth factor-β (TGF-ß) pathway activation 
(Trionfini et al, 2015). Interestingly miR-193b-3p has been shown to target TGF-β2 
and TGFBR3 3’-untranslated regions suggesting a potential modulation of the 
pathway (Hou et al, 2015; Thiery, 2003; Zhou et al, 2016).  
Our data suggest that integrating miR-193b-3p expression with clinical 
variables leads to a highly sensitive predictive model for the determination of risk of 
comorbidities in patients undergoing RN for RCC. Validation of our findings in 
prospective cohorts of patients receiving RN and NSS for kidney cancer is currently 
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ongoing. Matched analysis of tissues, plasma and urine will test the robustness of 
this marker and its applicability to clinical practice.  
 
 
Acknowledgments  
The results relative to miR-193b expression in human RCC and their matching 
normal tissues published here are partially based upon data generated by The 
Cancer Genome Atlas pilot project established by the NCI and NHGRI. Information 
about TCGA, and the investigators and institutions that constitute the TCGA research 
network can be found at http://cancergenome.nih.gov. 
This work was supported by Cancer Research UK (grant number CEA A18052), 
European Union FP7 (grant number CIG 334261) and the National Institute for 
Health Research (NIHR) Biomedical Research Centre (BRC) at The Royal Marsden 
NHS Foundation Trust and The Institute of Cancer Research (grant numbers A62, 
A100, A101) to NV, by an international research fellowship from the Italian Society of 
Nephrology to FT and by the Institute of Cancer Research Kidney Cancer Appeal to 
FT and NV. 
 
Author contributions: NV and FT had full access to all data in the study and take 
responsibility for data integrity and accuracy of data analysis. Study concept and 
design: FT, NV. Acquisition of data: FT, MG, AL, GDA, LC, CB, MF, JCH, LC, CC. 
Analysis and interpretation of data: FT, AL, LC, MF, CB, JCH. Drafting of the 
manuscript: FT, AL, JCH, CB, NV. Critical revision of the manuscript for important 
20 
 
intellectual content: All the authors. Statistical analysis: AL. Funding: FM, PM, NV. 
Administrative, technical, or material support: FT, MG, AL, GDA, LC, CB, MF, JCH, 
LZ, LC, CC, HL, MTSA, GC,MR, PR, RB, AB, AS, FB. Supervision: FM, NV. 
 
21 
 
References: 
Arner E, Mejhert N, Kulyte A, Balwierz PJ, Pachkov M, Cormont M, Lorente-Cebrian 
S, Ehrlund A, Laurencikiene J, Heden P, Dahlman-Wright K, Tanti JF, Hayashizaki Y, 
Ryden M, Dahlman I, van Nimwegen E, Daub CO, Arner P (2012) Adipose Tissue 
MicroRNAs as Regulators of CCL2 Production in Human Obesity. Diabetes 61(8): 
1986-1993 
 
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and 
powerful approach to multiple testing. Journal of the Royal Statistical Socirty Series B 
(Methodological) 57(1): 289-300 
 
Cancer Genome Atlas Research N (2013) Comprehensive molecular 
characterization of clear cell renal cell carcinoma. Nature 499(7456): 43-9 
 
Capitanio U, Larcher A, Terrone C, Antonelli A, Volpe A, Fiori C, Furlan M, Deho F, 
Minervini A, Serni S, Porpiglia F, Trevisani F, Salonia A, Carini M, Simeone C, 
Montorsi F, Bertini R (2016) End-Stage Renal Disease After Renal Surgery in 
Patients with Normal Preoperative Kidney Function: Balancing Surgical Strategy and 
Individual Disorders at Baseline. Eur Urol 
 
Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, 
Vecchione A, Croce CM, Shapiro CL, Huebner K (2013) Integrated microRNA and 
mRNA signatures associated with survival in triple negative breast cancer. PLoS One 
8(2): e55910 
 
22 
 
Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, 
Kallioniemi O, Mengual L, Schlomm T, Visakorpi T (2011) MicroRNA in prostate, 
bladder, and kidney cancer: a systematic review. Eur Urol 59(5): 671-81 
 
Eknoyan G, Lameire N, Eckardt KU, Kasiske BL, Wheeler DC, Abboud OI, Adler S, 
Agarwal R (2013) KDIGO 2012 Clinical Practice Guideline for the Evaluation and 
Management of Chronic Kidney Disease. Kidney International Supplements 3(1): 5-
14 
 
Elvira-Matelot E, Zhou XO, Farman N, Beaurain G, Henrion-Caude A, Hadchouel J, 
Jeunemaitre X (2010) Regulation of WNK1 expression by miR-192 and aldosterone. 
J Am Soc Nephrol 21(10): 1724-31 
 
Fabbri M, Valeri N, Calin GA (2009) MicroRNAs and genomic variations: from 
Proteus tricks to Prometheus gift. Carcinogenesis 30(6): 912-7 
 
Fasanaro P, D'Alessandra Y, Magenta A, Pompilio G, Capogrossi MC (2015) 
microRNAs: Promising Biomarkers and Therapeutic Targets of Acute Myocardial 
Ischemia. Curr Vasc Pharmacol 13(3): 305-15 
 
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, 
Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: 
estimates for 40 countries in 2012. Eur J Cancer 49(6): 1374-403 
 
23 
 
Gastaldi C, Bertero T, Xu N, Bourget-Ponzio I, Lebrigand K, Fourre S, Popa A, 
Cardot-Leccia N, Meneguzzi G, Sonkoly E, Pivarcsi A, Mari B, Barbry P, Ponzio G, 
Rezzonico R (2014) miR-193b/365a cluster controls progression of epidermal 
squamous cell carcinoma. Carcinogenesis 35(5): 1110-20 
 
Haetscher N, Feuermann Y, Wingert S, Rehage M, Thalheimer FB, Weiser C, 
Bohnenberger H, Jung K, Schroeder T, Serve H, Oellerich T, Hennighausen L, 
Rieger MA (2015) STAT5-regulated microRNA-193b controls haematopoietic stem 
and progenitor cell expansion by modulating cytokine receptor signalling. Nat 
Commun 6: 8928 
 
Hou C, Yang Z, Kang Y, Zhang Z, Fu M, He A, Zhang Z, Liao W (2015) MiR-193b 
regulates early chondrogenesis by inhibiting the TGF-beta2 signaling pathway. FEBS 
Lett 589(9): 1040-7 
 
Ikeda Y, Tanji E, Makino N, Kawata S, Furukawa T (2012) MicroRNAs associated 
with mitogen-activated protein kinase in human pancreatic cancer. Mol Cancer Res 
10(2): 259-69 
 
Iwamoto N, Vettori S, Maurer B, Brock M, Pachera E, Jungel A, Calcagni M, Gay RE, 
Whitfield ML, Distler JH, Gay S, Distler O (2016) Downregulation of miR-193b in 
systemic sclerosis regulates the proliferative vasculopathy by urokinase-type 
plasminogen activator expression. Ann Rheum Dis 75(1): 303-10 
 
Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, De 
la Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, 
24 
 
Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJ 
(2007) Multi-institutional validation of a new renal cancer-specific survival nomogram. 
J Clin Oncol 25(11): 1316-22 
 
Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, 
Linsley PS, Johnson JM (2005) Microarray analysis shows that some microRNAs 
downregulate large numbers of target mRNAs. Nature 433(7027): 769-73 
 
Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, 
Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex 
A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5): 913-
24 
 
Maluf DG, Dumur CI, Suh JL, Scian MJ, King AL, Cathro H, Lee JK, Gehrau RC, 
Brayman KL, Gallon L, Mas VR (2014) The urine microRNA profile may help monitor 
post-transplant renal graft function. Kidney Int 85(2): 439-449 
 
Mariusdottir E, Jonsson E, Marteinsson VT, Sigurdsson MI, Gudbjartsson T (2013) 
Kidney function following partial or radical nephrectomy for renal cell carcinoma: a 
population-based study. Scand J Urol 47(6): 476-82 
 
Mendell JT, Olson EN (2012) MicroRNAs in stress signaling and human disease. Cell 
148(6): 1172-87 
 
25 
 
Mets E, Van der Meulen J, Van Peer G, Boice M, Mestdagh P, Van de Walle I, 
Lammens T, Goossens S, De Moerloose B, Benoit Y, Van Roy N, Clappier E, Poppe 
B, Vandesompele J, Wendel HG, Taghon T, Rondou P, Soulier J, Van Vlierberghe P, 
Speleman F (2015) MicroRNA-193b-3p acts as a tumor suppressor by targeting the 
MYB oncogene in T-cell acute lymphoblastic leukemia. Leukemia 29(4): 798-806 
 
Mladinov D, Liu Y, Mattson DL, Liang M (2013) MicroRNAs contribute to the 
maintenance of cell-type-specific physiological characteristics: miR-192 targets 
Na+/K+-ATPase beta1. Nucleic Acids Res 41(2): 1273-83 
 
Nashar K, Egan BM (2014) Relationship between chronic kidney disease and 
metabolic syndrome: current perspectives. Diabetes Metab Syndr Obes 7: 421-35 
 
Neviani P, Fabbri M (2015) Exosomic microRNAs in the Tumor Microenvironment. 
Front Med (Lausanne) 2: 47 
 
Nuovo GJ, Garofalo M, Valeri N, Roulstone V, Volinia S, Cohn DE, Phelps M, 
Harrington KJ, Vile R, Melcher A, Galanis E, Sehl S, Adair R, Scott K, Rose A, 
Toogood G, Coffey MC (2012) Reovirus-associated reduction of microRNA-let-7d is 
related to the increased apoptotic death of cancer cells in clinical samples. Mod 
Pathol 25(10): 1333-44 
 
Remuzzi G, Grinyo J, Ruggenenti P, Beatini M, Cole EH, Milford EL, Brenner BM 
(1999) Early experience with dual kidney transplantation in adults using expanded 
donor criteria. Double Kidney Transplant Group (DKG). J Am Soc Nephrol 10(12): 
2591-8 
26 
 
 
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 
66(1): 7-30 
 
Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. 
Curr Opin Cell Biol 15(6): 740-6 
 
Trionfini P, Benigni A, Remuzzi G (2015) MicroRNAs in kidney physiology and 
disease. Nat Rev Nephrol 11(1): 23-33 
 
Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock V, Hart JR, Ueno 
L, Grivennikov SI, Lovat F, Paone A, Cascione L, Sumani KM, Veronese A, Fabbri M, 
Carasi S, Alder H, Lanza G, Gafa R, Moyer MP, Ridgway RA, Cordero J, Nuovo GJ, 
Frankel WL, Rugge M, Fassan M, Groden J, Vogt PK, Karin M, Sansom OJ, Croce 
CM (2014) MicroRNA-135b promotes cancer progression by acting as a downstream 
effector of oncogenic pathways in colon cancer. Cancer Cell 25(4): 469-83 
 
Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating 
prediction models. Med Decis Making 26(6): 565-74 
 
Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini 
J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, 
Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, 
Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, 
Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, 
27 
 
Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi 
N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, 
Croce CM (2010) Reprogramming of miRNA networks in cancer and leukemia. 
Genome Res 20(5): 589-99 
 
Westland R, Schreuder MF, van Goudoever JB, Sanna-Cherchi S, van Wijk JA 
(2014) Clinical implications of the solitary functioning kidney. Clin J Am Soc Nephrol 
9(5): 978-86 
 
Wilflingseder J, Regele H, Perco P, Kainz A, Soleiman A, Muhlbacher F, Mayer B, 
Oberbauer R (2013) miRNA Profiling Discriminates Types of Rejection and Injury in 
Human Renal Allografts. Transplantation 95(6): 835-841 
 
Winter J, Jung S, Keller S, Gregory RI, Diederichs S (2009) Many roads to maturity: 
microRNA biogenesis pathways and their regulation. Nat Cell Biol 11(3): 228-34 
 
Xu P, Zhao Y, Liu M, Wang Y, Wang H, Li YX, Zhu X, Yao Y, Wang H, Qiao J, Ji L, 
Wang YL (2014) Variations of microRNAs in human placentas and plasma from 
preeclamptic pregnancy. Hypertension 63(6): 1276-84 
 
Zhou X, Li Q, Xu J, Zhang X, Zhang H, Xiang Y, Fang C, Wang T, Xia S, Zhang Q, 
Xing Q, He L, Wang L, Xu M, Zhao X (2016) The aberrantly expressed miR-193b-3p 
contributes to preeclampsia through regulating transforming growth factor-beta 
signaling. Sci Rep 6: 19910 
 
28 
 
 
Figure 1. Schematic overview of the study. * estimated Glomerular Fraction Rate 
(eGFR) > 60 ml/min based on CKD-EPI formula 2009. CKD= Chronic Kidney 
Disease. RN= Radical Nephrectomy. ISH= In-Situ Hybridization. 
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Figure 2. Heatmap showing miR expression in medulla of patients with normal 
kidney function (NKF) compared to patients developing Chronic Kidney Disease 
(CKD) 12 months post nephrectomy for RCC. miRs with p  value ≤0.1 are shown.  
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Figure 3. Decision Curve Analysis plot comparing performance of a predictive score 
including clinical variables (base model) alone or in combination with specific miRs. 
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Figure 4. MiR-193b-3p In-Situ Hybridization (ISH) in “normal” parenchyma adjacent 
to RCC. ISH was conducted in samples characterized by high (n=5) and low (n=5) 
miR-193b-3p expression at nCounter and RT-PCR analysis in patients with high pre-
operative eGFR.  MiR expression was detectable as a grainy blue cytoplasmic 
staining. In cases with low miR-193b expression, only faint miR-193b staining was 
observed in the collector ducts in the medulla and in distal convoluted tubule and in 
glomerular endothelial cells in the cortex. High-miR-193b cases were characterized 
by a moderate to strong miRNA expression in the inflammatory infiltrate and 
fibroblasts present in both renal compartments. A significant miR-193b 
overexpression was observed in atrophic and swollen tubules and ducts within the 
medulla.  
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Table 1. Descriptive characteristics of 71 patients treated with radical nephrectomy 
for kidney cancer 
Table 1. Descriptive characteristics of 71 patients treated with radical nephrectomy for kidney cancer 
Variable Overall 
Age, years   
  Median 65 
  IQR 55-71 
Gender  
  Male 50 (70.4) 
  Female 21 (30.6) 
Preoperative eGFR, mL/min   
  Median 90 
  IQR 78-97 
Tumour size, mm  
  Median 65 
  IQR 53-80 
Kidney dimension, mm  
  Median 125 
  IQR 110-145 
Diabetes  
  No 57 (80.2) 
  Yes  14 (20.8) 
Data presented as frequencies and percentages (numbers between brackets) unless otherwise 
specified. IQR: Interquartile range.  
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Table 2. Logistic regression analysis predicting development of postoperative chronic kidney disease in 71 patients treated with 
radical nephrectomy for kidney cancer. 
Table 2. Logistic regression analysis predicting development of postoperative chronic kidney disease in 71 patients treated with radical nephrectomy for kidney 
cancer. 
Predictors 
Base Model Model 1 - miR193b Model 2 - miR363b Model 3 - miR139b Model 4 - miR365a 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
microRNA - - 
2.28 (1.42-
4.14) 
0.002 
6.28 (1.42-
42.4) 
0.04 
5.86 (1.82-
24.6) 
0.01 
2.18 (1.30-
4.19) 
0.01 
Age 
1.04 (0.97-
1.11) 
0.3 
1.02  (0.95-
1.09) 
0.6 
1.03 (0.97-
1.11) 
0.4 
1.02 (0.96-
1.10) 
0.5 
1.03 (0.96-
1.10) 
0.5 
Gender           
  Female   Ref. - Ref. - Ref. - Ref. - Ref. - 
  Male 
6.07 (1.50-
30.7) 
0.02 
4.69 (0.93-
31.3) 
0.08 
5.25 (1.15-
30.1) 
0.04 
6.47 (1.33-
40.5) 
0.03 
7.27 (1.44-
49.5) 
0.03 
Preoperative eGFR 
0.93 (0.88-
0.99) 
0.02 
0.91 (0.84-
0.97) 
0.01 
0.93 (0.87-
0.98) 
0.02 
0.91 (0.85-
0.97) 
0.01 
0.91 (0.84-
0.97) 
0.01 
Diabetes           
  No Ref. - Ref. - Ref. - Ref. - Ref. - 
  Yes  
2.48 (0.62-
11.6) 
0.2 
6.86 (1.26-
52.0) 
0.04 
4.38 (0.99-
23.1) 
0.06 
4.94 (1.04-
28.1) 
0.05 
5.32 (1.08-
33.5) 
0.05 
Predictive accuracy 
(%) 
81 88 83 86 86 
OR: Odds ratio. CI: Confidence interval  
